| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 453.28 KB | Adobe PDF |
Authors
Abstract(s)
As neoplasias malignas sĆ£o, na atualidade, um verdadeiro problema de saĆŗde pĆŗblica correspondendo Ć segunda causa de morte a nĆvel mundial. A carga global do cancro estĆ” a aumentar rapidamente e perspetiva-se que continue a aumentar. O cancro pancreĆ”tico, embora nĆ£o sendo dos cancros mais incidentes (posicionando-se no 11Āŗ lugar a nĆvel mundial) corresponde, mundialmente, Ć sĆ©tima causa de morte por cancro, em ambos os sexos. Verifica-se uma elevada mortalidade nos pacientes diagnosticados com esta patologia, nĆŗmeros esses que espelham praticamente os nĆŗmeros dos casos de incidĆŖncia do mesmo, refletindo a sua natureza letal. O aumento da incidĆŖncia do cancro traz continuamente novos desafios e a necessidade de desenvolver biomarcadores que possibilitem a identificaĆ§Ć£o precoce, a monitorizaĆ§Ć£o, terapĆŖutica e prognĆ³stico das neoplasias malignas. Os microRNAs sĆ£o pequenas sequĆŖncias nĆ£o-codificantes de RNA cuja funĆ§Ć£o assenta na regulaĆ§Ć£o da expressĆ£o gĆ©nica. Dada a sua importante funĆ§Ć£o, nĆ£o surpreende que a sua desregulaĆ§Ć£o esteja implicada em diversos processos patolĆ³gicos, nomeadamente o cancro. Estas pequenas sequĆŖncias tĆŖm vindo a ser investigadas, apontando para uma funĆ§Ć£o promissora como biomarcadores. No que se refere ao cancro pancreĆ”tico, jĆ” vĆ”rios estudos identificaram microRNAs circulantes derivados do tumor que se encontram sobre ou sub regulados, caracterizando-os como biomarcadores, nomeadamente de diagnĆ³stico e prognĆ³stico, sendo que alguns dos identificados incluem microRNA-21, microRNA-210, microRNA-155. Considerando a elevada taxa de metastizaĆ§Ć£o do cancro pancreĆ”tico, a identificaĆ§Ć£o de microRNAs (microRNA 10b, 21, entre outros) motiva a sua utilizaĆ§Ć£o como potenciais biomarcadores que refletem a propensĆ£o de metĆ”stase. Todos estes achados representam possĆveis novos biomarcadores com potencial de definir a mais adequada intervenĆ§Ć£o terapĆŖutica nestes doentes. Com o presente trabalho pretende-se efetuar uma revisĆ£o das potencialidades dos microRNAs e a sua utilizaĆ§Ć£o como biomarcadores no cancro pancreĆ”tico.
Malignant neoplasms are a worldwide threat to public health, being the second cause of death. The overall burden of cancer is rising fast and it is expected to continue to increase in the coming decades. Pancreatic cancer, although not the most prevalent cancer, being only the 11th most widespread worldwide, it is the seventh cause of death by cancer, for both genders. Patients diagnosed with pancreatic cancer have a high mortality rate, roughly the same number of diagnosed cases, hence its lethal nature. The increase in cancer incidence worldwide fosters new challenges and the need to develop technologies to help fight this burden. Among them, biomarkers that can help an early identification of cancer, monitorization, therapy, and aid in prognostics are promising future solutions. MicroRNAs are small non-coding sequences of RNA that regulate gene expression. Given their important function, it is known that their deregulation is involved in various pathologic processes, namely cancer. These small molecules have been extensively researched as biomarkers. On pancreatic cancer, tumour circulating miRNAās have been identified, usually over or underregulated, and have been characterized as diagnostic or prognostic biomarkers, namely miRNA-21, miRNA-210 and miRNA-155 which are some of the identified sequences in pancreatic cancer. This type of cancer has a high metastization rate, and the identification of miRNAās like 10b, 21 and others, which are related to metastization phenomena, strengthens research on miRNAās to further understand the evolution and behaviour of pancreatic cancer, and ultimately to be used as a therapeutic agent. This work intends to be a review of the potential aplications of microRNAs and their putative use as biomarkers in pancreatic cancer
Malignant neoplasms are a worldwide threat to public health, being the second cause of death. The overall burden of cancer is rising fast and it is expected to continue to increase in the coming decades. Pancreatic cancer, although not the most prevalent cancer, being only the 11th most widespread worldwide, it is the seventh cause of death by cancer, for both genders. Patients diagnosed with pancreatic cancer have a high mortality rate, roughly the same number of diagnosed cases, hence its lethal nature. The increase in cancer incidence worldwide fosters new challenges and the need to develop technologies to help fight this burden. Among them, biomarkers that can help an early identification of cancer, monitorization, therapy, and aid in prognostics are promising future solutions. MicroRNAs are small non-coding sequences of RNA that regulate gene expression. Given their important function, it is known that their deregulation is involved in various pathologic processes, namely cancer. These small molecules have been extensively researched as biomarkers. On pancreatic cancer, tumour circulating miRNAās have been identified, usually over or underregulated, and have been characterized as diagnostic or prognostic biomarkers, namely miRNA-21, miRNA-210 and miRNA-155 which are some of the identified sequences in pancreatic cancer. This type of cancer has a high metastization rate, and the identification of miRNAās like 10b, 21 and others, which are related to metastization phenomena, strengthens research on miRNAās to further understand the evolution and behaviour of pancreatic cancer, and ultimately to be used as a therapeutic agent. This work intends to be a review of the potential aplications of microRNAs and their putative use as biomarkers in pancreatic cancer
Description
Keywords
Biomarcadores Circulantes Cancro PancreƔtico Microrna